Comparison · NCT04535531-5258ccf5
SB206 vs Placebo: 90% Reduction From Baseline in the Number of All Treatable MC at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SB206 vs Placebo: 90% Reduction From Baseline in the Number of All Treatable MC at Week 12. Trial comparisons, record NCT04535531-5258ccf5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04535531-5258ccf5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.43 | 0.385 | 0.477 | wilson | |
| Risk in group 2 | 0.239 | 0.202 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | 0.191 | 0.129 | 0.25 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.8 | 1.48 | 2.19 | log | |
| Odds ratio, group 1 over group 2 | 2.4 | 1.8 | 3.2 | log | |
| Number needed to treat, for one more participant with the outcome on SB206 than on Placebo | 5.24 | 3.99 | 7.73 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SB206 | SB206 gel applied topically, once daily for 12 weeks. | 191 | 444 | OG000 |
| Group 2 | Placebo | Placebo gel applied topically, once daily for 12 weeks. | 107 | 447 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- 90% Reduction From Baseline in the Number of All Treatable MC at Week 12
- Description
- Percent (proportion) of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Week 12
- Time frame
- 12 Weeks
- Population
- ITT
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
- NCT number
- NCT04535531
- Phases
- PHASE3
- Conditions
- Molluscum Contagiosum
- Interventions
- SB206 10.3% berdazimer, vehicle gel
- Lead sponsor
- Novan, Inc.
- Results first posted
- 2023-01-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04535531?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04535531-5258ccf5